Fosun Pharma Offloads $124m Stake in Hospital Group to Warburg Pincus - Nikkei

InvestingMar 14 12:42 ET

Shanghai Fosun Pharmaceutical (Group)'s Subsidiary PNH Drug Gets NMPA's Nod for Clinical Trials; Shares Rise 4%

MT NewswiresMar 14 03:57 ET

AI and policy are driving forces! Hong Kong pharmaceutical stocks collectively "rebound" with WUXI BIO surging over 14% to lead the Industry.

① What technological breakthroughs have driven the improvement of research and development efficiency in the Biomedical Industry? ② What are the reasons for the leading increase in WuXi's affiliated companies?

cls.cnMar 14 00:35 ET

Fosun Pharma Gets Clinical Trial Approval for Blood Disorder Drug

MT NewswiresMar 13 23:08 ET

Hong Kong stocks are experiencing fluctuations | CRO Concept stocks are warming up. The integration of AI and CXO has entered a new stage. Institutions claim that the external environment for CRO may be improving.

As of the time of writing, the CRO Concept has warmed up, with VIVA BIOTECH (01873) rising by 11.89% to 1.6 HKD; WUXI BIO (02269) increasing by 10.3% to 25.7 HKD; PHARMARON (03759) up by 5.67% to 16.04 HKD; and TIGERMED (03347) climbing by 5.86% to 37.05 HKD.

Zhitong FinanceMar 13 22:47 ET

Announcement highlights | AIA's new business value for the year 2024 increased by 18% year-on-year to 4.712 billion USD, proposing a final dividend of 130.98 Hong Kong cents per share; Weibo's net profit for the fiscal year 2024 decreased by 12.2% year-on

BOC AVIATION's Net income for 2024 increased by about 20%; YUEXIUTRANSPORT's revenue declined year-on-year last year.

cls.cnMar 13 20:22 ET